SCHEMBL6009848

SCHEMBL6009848

CC(NCCCS(=O)(=O)O)c1ccccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADRA2C P18825 2/20 0.40
SLC6A2 P23975 2/20 0.40
HTR2C P28335 2/20 0.40
SLC6A4 P31645 2/20 0.40
OPRM1 P35372 2/20 0.40
DRD3 P35462 2/20 0.40
CASR P41180 2/20 0.40
MLNR O43193 1/20 0.40
ABCB11 O95342 1/20 0.40
ADRB1 P08588 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CYP2D6 P10635 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD2 P14416 1/20 0.40
CHRM3 P20309 1/20 0.40
GLRA1 P23415 1/20 0.40
AVPR2 P30518 1/20 0.40
HRH1 P35367 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10278360 0.81 CNR2 (0.36) HPGDSMN1; SMN2SLC6A4ADRB1CYP2D6
SCHEMBL10277846 0.79 CNR2 (0.35) HPGDSMN1; SMN2SLC6A4CNR2ACP3
SCHEMBL353739 0.77 CASR (0.51) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL353163 0.77 CASR (0.51) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL12945117 0.77 HPGD (0.41) HPGDSMN1; SMN2ADRA2CSLC6A2HTR2C
SCHEMBL9286395 0.77 HPGD (0.41) HPGDSMN1; SMN2ADRA2CSLC6A2HTR2C
SCHEMBL10231050 0.76 CYP3A4 (0.53) HPGDSMN1; SMN2SLC6A2SLC6A4OPRM1
SCHEMBL14099965 0.76 CYP3A4 (0.53) HPGDSMN1; SMN2SLC6A2SLC6A4OPRM1
SCHEMBL10231054 0.76 CYP3A4 (0.53) HPGDSMN1; SMN2SLC6A2SLC6A4OPRM1
SCHEMBL6009058 0.76 CA1 (0.40) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR HPGD 1617/4885SMN1; SMN2 141/4885ADRA2C 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.